Nasus Pharma Ltd. received a Notice of Effectiveness from the U.S. Securities and Exchange Commission on August 21, 2026. This regulatory milestone confirms the company's registration statement is now active.
The effectiveness allows Nasus Pharma to proceed with public offerings or other registered securities transactions. This access to public markets provides essential funding for ongoing research and development.
Nasus Pharma currently develops clinical-stage intranasal treatments for allergic reactions and nausea. The company will utilize the capital to advance these pipeline products through necessary clinical trials.